Morgan Stanley lowered the firm’s price target on SI-Bone to $19 from $21 and keeps an Overweight rating on the shares after what the firm calls “another solid quarter with positive steps towards breakeven.” Management having committed to positive adjusted EBITDA in Q4 and outlining the path towards full-year 2025 positive EBITDA “should be well-received,” the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SIBN:
- SI-BONE To Present at Canaccord Genuity 44th Annual Growth Conference on August 14, 2024
- SI-Bone Welcomes Daniel Wolf as New Board Member
- SI-BONE, Inc. Reports Financial Results for the Second Quarter 2024
- Is SIBN a Buy, Before Earnings?
- SI-BONE To Report Second Quarter 2024 Financial Results on August 5, 2024